Application of genetically engineered Salmonella typhimurium for interferon-gamma-induced therapy against melanoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yoon, Wonsuck | - |
dc.contributor.author | Park, Yoo Chang | - |
dc.contributor.author | Kim, Jinseok | - |
dc.contributor.author | Chae, Yang Seok | - |
dc.contributor.author | Byeon, Jung Hye | - |
dc.contributor.author | Min, Sang-Hyun | - |
dc.contributor.author | Park, Sungha | - |
dc.contributor.author | Yoo, Young | - |
dc.contributor.author | Park, Yong Keun | - |
dc.contributor.author | Kim, Byeong Mo | - |
dc.date.accessioned | 2021-09-03T11:16:30Z | - |
dc.date.available | 2021-09-03T11:16:30Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2017-01 | - |
dc.identifier.issn | 0959-8049 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/85003 | - |
dc.description.abstract | Salmonella have been experimentally used as anti-cancer agents, because they show selective growth in tumours. In this study, we genetically modified attenuated Salmonella typhimurium to express and secrete interferon-gammS. typhimurium or S. typhimurium expressing empty vector (S. typhimurium [Vec]) in a natural killer (NK) cell-dependent manner. Moreover, genetically modified Salmonella, including S. typhimurium (IFN-gamma), showed little toxicity to normal tissues with no observable adverse effects. However, S. typhimurium (IFN-gamma)-mediated tumour suppression was attributed to direct killing of tumour cells rather than to stable anti-tumour immunity. Collectively, these results suggest that tumour-targeted therapy using S. typhimurium (IFN-gamma) has potential for melanoma treatment. (C) 2016 Elsevier Ltd. All rights reserved.a (IFN-gamma) as a tumouricidal agent to enhance the therapeutic efficacy of Salmonella. IFN-gamma was fused to the N-terminal region (residues 1e160) of SipB (SipB160) for secretion from bacterial cells. Attenuated S. typhimurium expressing recombinant IFN-gamma (S. typhimurium (IFN-gamma)) invaded the melanoma cells and induced cytotoxicity. Subcutaneous administration of S. typhimurium (IFN-gamma) also efficiently inhibited tumour growth and prolonged the survival of C57BL/6 mice bearing B16F10 melanoma compared with administration of phosphate-buffered saline (PBS), unmodified S. typhimurium or S. typhimurium expressing empty vector (S. typhimurium [Vec]) in a natural killer (NK) cell-dependent manner. Moreover, genetically modified Salmonella, including S. typhimurium (IFN-gamma), showed little toxicity to normal tissues with no observable adverse effects. However, S. typhimurium (IFN-gamma)-mediated tumour suppression was attributed to direct killing of tumour cells rather than to stable anti-tumour immunity. Collectively, these results suggest that tumour-targeted therapy using S. typhimurium (IFN-gamma) has potential for melanoma treatment. (C) 2016 Elsevier Ltd. All rights reserved. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCI LTD | - |
dc.subject | TUMOR-TARGETED SALMONELLA | - |
dc.subject | IFN-GAMMA | - |
dc.subject | ATTENUATED SALMONELLA | - |
dc.subject | CANCER-THERAPY | - |
dc.subject | EXPRESSION | - |
dc.subject | CELLS | - |
dc.subject | SECRETION | - |
dc.subject | PROTEIN | - |
dc.subject | GROWTH | - |
dc.subject | DIFFERENTIATION | - |
dc.title | Application of genetically engineered Salmonella typhimurium for interferon-gamma-induced therapy against melanoma | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Yoon, Wonsuck | - |
dc.contributor.affiliatedAuthor | Chae, Yang Seok | - |
dc.contributor.affiliatedAuthor | Byeon, Jung Hye | - |
dc.contributor.affiliatedAuthor | Yoo, Young | - |
dc.contributor.affiliatedAuthor | Park, Yong Keun | - |
dc.identifier.doi | 10.1016/j.ejca.2016.10.010 | - |
dc.identifier.scopusid | 2-s2.0-84996619330 | - |
dc.identifier.wosid | 000390655400006 | - |
dc.identifier.bibliographicCitation | EUROPEAN JOURNAL OF CANCER, v.70, pp.48 - 61 | - |
dc.relation.isPartOf | EUROPEAN JOURNAL OF CANCER | - |
dc.citation.title | EUROPEAN JOURNAL OF CANCER | - |
dc.citation.volume | 70 | - |
dc.citation.startPage | 48 | - |
dc.citation.endPage | 61 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | TUMOR-TARGETED SALMONELLA | - |
dc.subject.keywordPlus | IFN-GAMMA | - |
dc.subject.keywordPlus | ATTENUATED SALMONELLA | - |
dc.subject.keywordPlus | CANCER-THERAPY | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | CELLS | - |
dc.subject.keywordPlus | SECRETION | - |
dc.subject.keywordPlus | PROTEIN | - |
dc.subject.keywordPlus | GROWTH | - |
dc.subject.keywordPlus | DIFFERENTIATION | - |
dc.subject.keywordAuthor | Genetically modified Salmonella typhimurium (S. typhimurium) | - |
dc.subject.keywordAuthor | Interferon-gamma (IFN-gamma) | - |
dc.subject.keywordAuthor | SipB160 | - |
dc.subject.keywordAuthor | Melanoma | - |
dc.subject.keywordAuthor | Treatment option for melanoma | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.